Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

"Isolated" low high-density lipoprotein cholesterol

V M Wilt¹, J G Gums

¹Department of Pharmacy Practice, University of Florida, Gainesville 32164, USA.

The Annals of Pharmacotherapy

|January 1, 1997

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?

Clinical and translational science·2016

Same author

Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide.

The pharmacogenomics journal·2014

Same author

Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.

Clinical pharmacology and therapeutics·2014

Same author

Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.

Journal of internal medicine·2014

Same author

Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.

The pharmacogenomics journal·2013

Same author

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.

The pharmacogenomics journal·2012

Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026

Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026

Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026

Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026

Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026

Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026

See all related articles

Low high-density lipoprotein cholesterol (HDL-C) increases coronary heart disease risk. Management is debated, with lifestyle changes recommended first, followed by other therapies like nicotinic acid.

Area of Science:

Cardiology
Lipidology

Background:

High-density lipoprotein cholesterol (HDL-C) plays a crucial role in lipid metabolism and cardiovascular health.
An isolated low HDL-C concentration is recognized as an independent risk factor for coronary heart disease (CHD).

Purpose of the Study:

To review the function, structure, and significance of HDL-C.
To evaluate current literature on the controversial management of isolated low HDL-C.

Main Methods:

A comprehensive MEDLINE search (1966-June 1996) identified relevant English-language clinical and review articles.
Key historical lipid studies, recent reviews, and clinical trials on HDL-C therapy were evaluated.

Main Results:

Discussion covers HDL-C structure, function, measurement, and the implications of isolated low HDL-C.

Related Experiment Videos

Lifestyle modifications (weight reduction, diet, smoking cessation, exercise) are primary management strategies.

Estrogen replacement, avoiding HDL-C-lowering drugs, and lipid-altering agents like nicotinic acid are presented as therapeutic options.

Conclusions:

Isolated low HDL-C is a significant CHD risk, though its management remains controversial.
Lifestyle modifications are universally recommended first-line treatments.
Further large-scale clinical trials are needed to establish optimal treatment strategies for isolated low HDL-C in primary and secondary CHD prevention.